TY - JOUR
T1 - Cost-effectiveness and Resource Allocation—Reply
AU - Harris, Anthony
AU - Hill, Suzanne R.
AU - Henry, David A.
PY - 2006/6/21
Y1 - 2006/6/21
N2 - [Extract] In Reply: Decisions on health care resource allocation, made with incomplete information, will always be imperfect. When faced with a fixed health budget and a goal of maximizing population health, as measured by an index such as the QALY, the optimal rule is to rank all independent health interventions in descending order of efficiency determined by dollar per QALY gained and then run down the list funding interventions until running out of money.1 At that point the last intervention funded would have a threshold ICER that reflected our willingness to pay for an extra QALY for a given budget. In cases in which budgets are small (as in low-income countries), the threshold ICER will have to be much lower than in high-income countries; this is the basis of proposals for differential pricing of essential medicines, which attempts to equalize opportunity costs in different settings.2 In cases in which a new drug is likely to have a major impact on the total budget (and perhaps displace interventions that have a low cost per QALY), we should use a higher threshold value. So the cost-effectiveness threshold, budgets, and affordability are always linked.
AB - [Extract] In Reply: Decisions on health care resource allocation, made with incomplete information, will always be imperfect. When faced with a fixed health budget and a goal of maximizing population health, as measured by an index such as the QALY, the optimal rule is to rank all independent health interventions in descending order of efficiency determined by dollar per QALY gained and then run down the list funding interventions until running out of money.1 At that point the last intervention funded would have a threshold ICER that reflected our willingness to pay for an extra QALY for a given budget. In cases in which budgets are small (as in low-income countries), the threshold ICER will have to be much lower than in high-income countries; this is the basis of proposals for differential pricing of essential medicines, which attempts to equalize opportunity costs in different settings.2 In cases in which a new drug is likely to have a major impact on the total budget (and perhaps displace interventions that have a low cost per QALY), we should use a higher threshold value. So the cost-effectiveness threshold, budgets, and affordability are always linked.
UR - http://www.scopus.com/inward/record.url?scp=33745228472&partnerID=8YFLogxK
U2 - 10.1001/jama.295.23.2723-b
DO - 10.1001/jama.295.23.2723-b
M3 - Letter
AN - SCOPUS:33745228472
SN - 0098-7484
VL - 295
SP - 2723
EP - 2724
JO - Journal of the American Medical Association
JF - Journal of the American Medical Association
IS - 23
ER -